Biotheus Enters into an Agreement with Alligator Bioscience to Develop Bispecific Molecules in Greater China

Shots:

• Alligator to receive ~52M in development milestones including $1M up front, $90M as option fee and royalties on sales and share of sub-license revenue. Biotheus to get right to an antibody from ALLIGATOR-GOLD to develop up to three bispecific molecules in Greater China with an option to expand the license for global rights
• The agreement provides entrance to the Alligator’s antibody library in China and proven its expertise in developing antibodies against TNFR family members
• ALLIGATOR-GOLD is a human Ab library containing 60B+ unique antibody fragments and has five leading clinical and preclinical drug candidates including ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144

Click here to­ read full press release/ article | Ref: PRnewswire| Image: Camegie